Symbols

IMDX

Insight Molecular·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMDX

Insight Molecular Diagnostics Inc.

A company focused on the field of molecular diagnostics,developing precision medicine technologies primarily in the field of cancer care

Industry

Biological Technology

Established Date

Listing Date

03/17/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.imdxinc.com

Security Type

Common stock

Office address

2 International Plaza Dr. Suite 510 Nashville Tennessee 37217

Business

Introduction

Insight Molecular Diagnostics Inc., was incorporated in California in September 2009. The company is a leading diagnostic technology company. The company's mission is to expand the availability of new molecular diagnostic tests, especially in the transplanted organ rejection test category. The company is developing molecular diagnostic test kits designed to enable its customers to conduct their own tests in-house to participate in the patient care value chain, which corresponds to the send test center laboratory model.

Company Financials

EPS

IMDX has released its 2025 Q4 earnings. EPS was reported at -0.72, versus the expected -0.56, missing expectations. The chart below visualizes how IMDX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IMDX has released its 2025 Q4 earnings report, with revenue of 1.14M, reflecting a YoY change of -23.35%, and net profit of -22.95M, showing a YoY change of 31.50%. The Sankey diagram below clearly presents IMDX's revenue sources and cost distribution.